Dare Bioscience Profit Margin

Dare Bioscience (DARE) currently reports a profit margin of -804.37% as of June 2026. That compares with -190.68% in the prior-year period — down 321.8% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Dare Bioscience's profit margin history and peer comparisons.

Dare Bioscience's profit margin decreased from -190.68% to -804.37% — a 321.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dare Bioscience's profit margin of -804.37% is lower than the Healthcare sector average of 21.34%. That is roughly 3870.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Dare Bioscience's current -804.37% should be judged against Healthcare norms (sector average: 21.34%) and against DARE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -804.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Dare Bioscience, and consider following DARE for alerts when major investors trade the stock.